Top news of the week: 05.04.2023.
bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results
bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results - read this article along with other careers information, tips and advice on BioSpace
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update - read this article along with other careers information, tips and advice on BioSpace
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus - read this article along with other careers information, tips and advice ...
NovelStem, Focused on a Patented Genetic Platform Technology for Anti-Cancer Therapies, Reports 2022 Results on Form 10-K
Boca Raton, Florida--(Newsfile Corp. - March 31, 2023) - NovelStem International Corp. (OTC Pink: NSTM), a development-stage company focused on the stem cell-based technology platform ...
Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023
Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Keystone Symposia Meeting ...
Kineta to Present at 22nd Annual Needham Healthcare Conference
Kineta to Present at 22nd Annual Needham Healthcare Conference - read this article along with other careers information, tips and advice on BioSpace
Scorpion Therapeutics Nominates STX-241 as Potentially Best-in-Class Fourth-Generation EGFR Inhibitor Development Candidate for the Treatment of Non-Small Cell Lung Cancer
Scorpion Therapeutics Nominates STX-241 as Potentially Best-in-Class Fourth-Generation EGFR Inhibitor Development Candidate for the Treatment of Non-Small Cell Lung Cancer - read this ...
Satellos Bioscience Announces 2022 Year End Financial Results and Operational Highlights
Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new a